Boryung Pharmaceutical announced on Feb. 27 that Korean and Mexican cardiovascular internal medicine experts shared the clinical effects and prescription cases of the Kanarb product group at the International Cardiovascular Intervention Conference held in Mexico on Feb. 23 (local time).At this event
The author is an analyst of Shinhan Investment Corp. He can be reached at shawn1225@shinhan.com. -- Ed. Strong in ETC market with Korea’s first hypertension drug KanarbBoryung Pharmaceutical stands out vs. other, generic drug-focused mid-tier pharmaceuticals in the domestic market, backed by its com
Boryung Pharmaceutical's new high blood pressure drug Tubero (a composite drug for dyslipidemia), which belongs to the company’s Kanarb family of hypertension drugs, made its debut in the Mexican market on Sept. 11 (Korea time).Tubero is Boryung’s fourth product to be introduced in Mexico, follo
Boryung Pharmaceutical and Vigencell announced on Sept. 8 that they have signed an R&D agreement to develop immunocyte therapy. The agreement will pave the way for the two companies to cooperate in development and commercialization of diverse immune-cell treatments.The agreement will help Vigencell
Boryung Pharmaceutical Co. announced on Aug. 19 that it has started selling its new antihypertensive combination drug Arahkor Duo, known as Dukarb in South Korea, in Mexico.Arahkor Duo is the third drug that Boryung launches in Mexico after Arahkor, known as Kanarb in South Korea, in 2014 and Diarak
Boryung Pharmaceutical is stepping up efforts to develop both biologics and chemical drugs.According to the pharmaceutical and biotechnology industry on Nov. 20, Boryung Pharma is seeking to enter the biopharmaceuticals market by developing an immune cell therapy treatment through its subsidiary Vig
Korean pharmaceutical companies are increasing the sales of their drugs that have not been selling well after development several years ago by improving their functions.According to pharmaceutical industry experts on October 25, the sales of major domestic drugs by the third quarter of this year sig
South Korea is situated on the periphery of the global pharmaceutical industry map. The global drug market reached US$1.1 trillion (1,244 trillion won) as of last year, the South Korean market stood at 21.7 trillion won (US$19.19 billion), accounting for a 0.012 percent of the total. There are no So
An increasing number of South Korean pharmaceutical and biotech companies are setting up branches, joint ventures and subsidiaries abroad.Particularly successful examples include Hanmi Pharmaceutical’s Beijing Hanmi Pharmaceutical established in 1996 and Ilyang Pharmaceutical’s Yangzhou Ilyang Pharm
Boryung Pharmaceutical Co., one of South Korea's largest pharmaceutical companies, has signed a contract worth 30 billion won (US$27.23 million) with Mexican pharmaceutical firm Stendhal International at the COEX in Samsung-dong, Seoul, on September 26 to supply its oral hypertension medication, suc
On February 26, the Korea Drug Research Association (KDRA) held its 17th annual awarding ceremony for new drug developers in Korea in Seoul. At the ceremony, Dong-A ST won half of the top prize with its oral diabetes drug Suganon Tab. Techniques applied to this drug have been exported to more than 2
Pharmaceutical companies are complaining that the government’s policy for lower drug prices is making it difficult for them to recover their significant development costs.One of their examples is Boryung Pharmaceutical’s Kanarb, the first hypertension drug developed by a Korean company. Although it
As domestic pharmaceutical companies have started gaining recognition of their new drug development capabilities overseas, they are expanding technology exports. As products newly-released abroad through technology exports are receiving a positive consumer response not only in emerging countries, in
The domestic pharmaceutical industry achieved excellent results in the research and development sector last year, including the approval for sales of the 21st new domestic medicine called Liavax, and the entry of new Korea-developed medicines such as Kanarb and Supect to the global market. Even thou